Neurol. praxi. 2024;25(4):274-281 | DOI: 10.36290/neu.2024.054

Extra-axial tumors of central nervous system - a pathologist's perspective

MUDr. Jiří Soukup, Ph.D.1, 2, 3, MUDr. Aleš Kohout, Ph.D.2, MUDr. Michaela May, Ph.D.4, prof. MUDr. David Netuka, Ph.D.4
1 Oddělení patologie, Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha
2 Fingerlandův ústav patologie, Fakultní nemocnice Hradec Králové a Lékařská fakulta v Hradci Králové, Univerzita Karlova v Praze
3 Ústav patologie 1. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice, Praha
4 Neurochirurgická a neuroonkologická klinika 1. LF UK a ÚVN v Praze

Extra-axial tumors originate from tissues outside the pia mater (arachnoid, dura mater, bone), distinct anatomically from the central nervous system parenchyma. Pathologically, these tumors comprise a diverse range of lesions with varying morphological, biological, genetic, and clinical characteristics. They are classified into numerous histopathological subgroups in the latest 5th edition of the WHO classification of CNS tumors. This article offers a concise overview of these tumors, exploring their genetic aspects and addressing key considerations in differential diagnosis. Emphasis is placed on meningiomas, cranial and paraspinal nerve tumors, non-meningothelial mesenchymal tumors, secondary meningeal tumors, and meningeal pseudotumors.

Keywords: meningioma, solitary fibrous tumor, hemangioblastoma, CENET, pseudo­tumors, meninges.

Accepted: August 26, 2024; Published: September 10, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soukup J, Kohout A, May M, Netuka D. Extra-axial tumors of central nervous system - a pathologist's perspective. Neurol. praxi. 2024;25(4):274-281. doi: 10.36290/neu.2024.054.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abedalthagafi M, Bi WL, Aizer, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016;18(5):649-655. doi:10.1093/neuonc/nov316. Go to original source... Go to PubMed...
    2. Agnihotri S, Jalali S, Wilson MR, et al. The genomic landscape of schwannoma. Nat Genet. 2016;48(11):1339-1348. doi:10.1038/ng.3688. Go to original source... Go to PubMed...
    3. Alexiev BA, Chou PM, Jennings LJ. Pathology of Melanotic Schwannoma. Arch Pathol Lab Med. 2018;142(12):1517-1523. doi:10.5858/arpa.2017-0162-RA. Go to original source... Go to PubMed...
    4. Antonescu CR, Owosho AA, Zhang L, et al. Sarcomas With CIC­‑rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases. Am J Surg Pathol. 2017;41(7):941-949. doi:10.1097/PAS.0000000000000846. Go to original source... Go to PubMed...
    5. Clark VE, Erson­‑Omay EZ, Serin A, et al. Genomic analysis of non­‑NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077-1080. doi:10.1126/science.1233009. Go to original source... Go to PubMed...
    6. Clark VE, Harmanci AS, Bai H, et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet. 2016;48(10):1253-1259. doi:10.1038/ng.3651. Go to original source... Go to PubMed...
    7. Cleven AH, Sannaa GA, Briaire­‑de Bruijn I, et al. Loss of H3K27 tri­‑methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29(6):582-590. doi:10.1038/modpathol.2016. 45. Go to original source...
    8. Daoud EV, Zhu K, Mickey B, et al. Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management. Acta Neuropathol Commun. 2022;10(1):56. doi:10.1186/s40478-022-01362-3 Go to original source... Go to PubMed...
    9. Eefting D, Schrage YM, Geirnaerdt MJ, et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol. 2009;33(1):50-57. doi:10.1097/PAS.0b013e31817eec2b. Go to original source... Go to PubMed...
    10. Folpe AL. "Hey! Whatever happened to hemangiopericytoma and fibrosarcoma?" An update on selected conceptual advances in soft tissue pathology which have occurred over the past 50 years. Hum Pathol. 2020;95:113-136. doi:10.1016/j.humpath.2019. 10. 001. Go to original source...
    11. Griewank KG, Koelsche C, van de Nes JAP, et al. Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. Clin Cancer Res. 2018;24(18):4494-4504. doi:10.1158/1078-0432.CCR-18-0763. Go to original source... Go to PubMed...
    12. Han N, Kim H, Min SK, et al. Meningeal Solitary Fibrous Tumors with Delayed Extracranial Metastasis. J Pathol Transl Med. 2016;50(2):113-121. doi:10.4132/jptm.2015. 10. 30. Go to original source...
    13. Hausler M, Schaade L, Ramaekers VT, et al. Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review. Hum Pathol. 2003;34(3)253-262. doi:10.1053/hupa.2003. 35. Go to original source...
    14. Cha YJ, Suh YL. Chordomas: Histopathological Study in View of Anatomical Location. J Korean Med Sci. 2019;34(13):e107. doi:10.3346/jkms.2019. 34. e107. Go to original source...
    15. Choudhury A, Magill ST, Eaton CD, et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet. 2022;54(5):649-659. doi:10.1038/s41588-022-01061-8. Go to original source... Go to PubMed...
    16. Jankovic D, Vuong K, Splavski B, et al. Supratentorial Hemangioblastoma in Adults: A Systematic Review and Comparison of Infratentorial and Spinal Cord Locations. World Neurosurg. 2023;173:48-62. doi:10.1016/j.wneu.2023. 02. 071. Go to original source...
    17. Jo VY, Fletcher CD. Epithelioid malignant peripheral nerve sheath tumor: clinicopathologic analysis of 63 cases. Am J Surg Pathol. 2015;39(5):673-682. doi:10.1097/PAS.0000000000000379. Go to original source... Go to PubMed...
    18. Joe WH, Lee CY, Kim CH, et al. Breast Cancer to Meningioma: A Rare Case of Tumor­‑to­‑Tumor Metastasis. Brain Tumor Res Treat. 2023;11(1):73-78. doi:10.14791/btrt.2022.0042. Go to original source... Go to PubMed...
    19. Kremenevski N, Schlaffer SM, Coras R, et al. Skull Base Chordomas and Chondrosarcomas. Neuroendocrinology. 2020;110(9-10):836-847. doi:10.1159/000509386. Go to original source... Go to PubMed...
    20. Kusters­‑Vandevelde HV, Kusters B, van Engen­‑van Grunsven AC, et al. Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. Brain Pathol. 2015;25(2):209-226. doi:10.1111/bpa.12241. Go to original source... Go to PubMed...
    21. Lee JC, Villanueva­‑Meyer JE, Ferris SP, et al. Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. Acta Neuropathol. 2019;137(3):521-525. doi:10.1007/s00401-019-01960-x. Go to original source... Go to PubMed...
    22. Li S, Chen Z, Le LQ. New insights into the neurofibroma tumor cells of origin. Neurooncol Adv. 2020;2(Suppl. 1):i13-i22. doi:10.1093/noajnl/vdz044. Go to original source... Go to PubMed...
    23. Lonser RR, Glenn GM, Walther M, et al. von Hippel­‑Lindau disease. Lancet. 2003;361(9374): 2059-2067. doi:10.1016/S0140-6736(03)13643-4. Go to original source... Go to PubMed...
    24. Macagno N, Vogels R, Appay R, et al. Crading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the Marseille Grading System in a cohort of 132 patients. Brain Pathol. 2019;29(1):18-27. doi:10.1111/bpa.12613. Go to original source... Go to PubMed...
    25. Martin­‑Broto J, Mondaza­‑Hernandez JL, Moura DS, Hindi N. A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons. Cancers (Basel). 2021;13(12). doi:10.3390/cancers13122913. Go to original source... Go to PubMed...
    26. McMenamin ME, Fletcher CD. Expanding the spectrum of malignant change in schwannomas: epithelioid malignant change, epithelioid malignant peripheral nerve sheath tumor, and epithelioid angiosarcoma: a study of 17 cases. Am J Surg Pathol. 2001;25(1):13-25. doi:10.1097/00000478-200101000-00002. Go to original source... Go to PubMed...
    27. Mehrian­‑Shai R, Yalon M, Moshe I, et al. Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis. BMC Genomics. 2016;17:56. doi:10.1186/s12864-016-2370-6. Go to original source... Go to PubMed...
    28. Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol. 2017;67:1-10. doi:10.1016/j.humpath.2017. 05. 010. Go to original source...
    29. Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray­‑based comparative analysis. Mod Pathol. 2008;21(12):1461-1469. doi:10.1038/modpathol.2008.144. Go to original source... Go to PubMed...
    30. Olbryt M. Molecular background of skin melanoma development and progression: therapeutic implications. Postepy Dermatol Alergol. 2019;36(2):129-138. doi:10.5114/ada.2019.84590. Go to original source... Go to PubMed...
    31. Ostrom QT, Price M, Neff C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2023;25(Supplement_4):iv1-iv99. doi:10.1093/neuonc/noad149. Go to original source... Go to PubMed...
    32. Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011;43(12):1256-1261. doi:10.1038/ng.1004. Go to original source... Go to PubMed...
    33. Rekhi B, Michal M, Ergen FB, et al. Poorly differentiated chordoma showing loss of SMARCB1/INI1: Clinicopathological and radiological spectrum of nine cases, including uncommon features of a relatively under­‑recognized entity. Ann Diagn Pathol. 2021;55:151809. doi:10.1016/j.anndiagpath.2021.151809. Go to original source... Go to PubMed...
    34. Robinson DR, Wu YM, Kalyana­‑Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45(2):180-185. doi:10.1038/ng.2509. Go to original source... Go to PubMed...
    35. Rushing EJ, Bouffard JP, McCall S, et al. Primary extracranial meningiomas: an analysis of 146 cases. Head Neck Pathol. 2009;3(2):116-130. doi:10.1007/s12105-009-0118-1. Go to original source... Go to PubMed...
    36. Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet. 1994;6(2):180-184. doi:10.1038/ng0294-180. Go to original source... Go to PubMed...
    37. Shively SB, Edwards NA, MacDonald TJ, et al. Developmentally Arrested Basket/Stellate Cells in Postnatal Human Brain as Potential Tumor Cells of Origin for Cerebellar Hemangioblastoma in von Hippel­‑Lindau Patients. J Neuropathol Exp Neurol. 2022;81(11):885-899. doi:10.1093/jnen/nlac073. Go to original source... Go to PubMed...
    38. Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29(1):4-13. doi:10.1038/modpathol.2015.134. Go to original source... Go to PubMed...
    39. Schweizer L, Thierfelder F, Thomas C, et al. Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. Acta Neuropathol. 2020;140(6):893-906. doi:10.1007/s00401-020-02218-7. Go to original source... Go to PubMed...
    40. Sievers P, Sill M, Blume C, et al. Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathol. 2021;141(2):281-290. doi:10.1007/s00401-020-02247-2. Go to original source... Go to PubMed...
    41. Sloan EA, Chiang J, Villanueva­‑Meyer JE, et al. Intracranial mesenchymal tumor with FET­‑CREB fusion­‑A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma­­‑like neoplasms. Brain Pathol. 2021;31(4):e12918. doi:10.1111/bpa.12918. Go to original source... Go to PubMed...
    42. Soukup J, Kasparova P, Vajda M, Ryska A. Adrenal metastasis of anaplastic meningioma: report of a rare case. Folia Neuropathol. 2019;57(4):366-372. doi:10.5114/fn.2019.91195. Go to original source... Go to PubMed...
    43. Soukup J, Kohout A, Vosmikova H, et al. Calcifying pseudoneoplasm of neuroaxis (CAPNON): a comprehensive immunohistochemical and morphological characterization of five cases. Virchows Arch. 2022;480(2):415-423. doi:10.1007/s00428-021-03177-4. Go to original source... Go to PubMed...
    44. Soukup J, Manethova M, Kohout A, et al. Cauda equina neuroendocrine tumors show biological features distinct from other paragangliomas and visceral neuroendocrine tumors. Virchows Arch. 2022. doi:10.1007/s00428-022-03441-1. Go to original source... Go to PubMed...
    45. Tomkinson C, Lu JQ. Meningioangiomatosis: A review of the variable manifestations and complex pathophysiology. J Neurol Sci. 2018;392:130-136. doi:10.1016/j.jns.2018. 07. 018. Go to original source...
    46. Torres­‑Mora J, Dry S, Li X, et al. Malignant melanotic schwannian tumor: a clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of "melanotic schwannoma". Am J Surg Pathol. 2014;38(1):94-105. doi:10.1097/PAS.0b013e3182a0a150. Go to original source... Go to PubMed...
    47. Ulici V, Hart J. Chordoma. Arch Pathol Lab Med. 2022;46(3):386-395. doi:10.5858/arpa.2020-0258-RA. Go to original source... Go to PubMed...
    48. van de Nes J, Gessi M, Sucker A, et al. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. J Neurooncol. 2016;127(3):435-444. doi:10.1007/s11060-015-2052-2. Go to original source... Go to PubMed...
    49. Velazquez Vega JE, Rosenberg AE. Microcystic meningioma of the calvarium: a series of 9 cases and review of the literature. Am J Surg Pathol. 2015;39(4):505-511. doi:10.1097/PAS.0000000000000347. Go to original source... Go to PubMed...
    50. Vortmeyer AO, Tran MG, Zeng W, et al. Evolution of VHL tumourigenesis in nerve root tissue. J Pathol. 2006;210(3):374-382. doi:10.1002/path.2062. Go to original source... Go to PubMed...
    51. Wang L, Zehir A, Sadowska J, et al. Consistent copy number changes and recurrent PRKAR1A mutations distinguish Melanotic Schwannomas from Melanomas: SNP­‑array and next generation sequencing analysis. Genes Chromosomes Cancer. 2015;54(8):463-471. doi:10.1002/gcc.22254. Go to original source... Go to PubMed...
    52. WHO. (2021). World Health Organization Classification of Tumours of the Central Nervous System. (5th ed.). Lyon: International Agency for Research on Cancer.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.